Modal DNA-values in prostate cancer patients with deferred therapy or endocrine therapy.
Modal DNA-values were assessed with flow cytometry in 269 patients with newly detected untreated prostate cancer. One hundred and seventy-two patients with low-grade, low-stage, non-metastasized cancers were followed without treatment and in this group initial tumor ploidy had no prognostic value. Ninety-seven patients with clinically more advanced prostate cancers were subjected to endocrine therapy and in this group ploidy was prognostic regarding cancer-related survival.
Adolfsson
J
J
Department of Urology and Radiobiology, Karolinska Hospital, Stockholm, Sweden.
Tribukait
B
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004273:DNA, Neoplasm / Q000032:analysis*; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics / Q000628:therapy; D011003:Ploidies; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy
D004273:DNA, Neoplasm